Fresh analysis suggests that patients who come off blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Published data in a prominent medical journal points out that while obese people often shed a large proportion of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users buying these medications must be aware of the potential of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass within about one and a half years.
Comparing Therapies
The research, which reviewed 37 of studies involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.
The team point out that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Explaining the Quick Regain
Experts believe the mode of action of the jabs explains the heightened weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels far above than normal might result in the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication leads to appetite is uncontrolled, making excessive eating much more probable."
An Ongoing Issue?
Health authorities suggest the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the significant potential of relapse, the therapy is often long-term.
This opinion is reinforced by pharmaceutical companies, who state that the findings "underscore the chronic character of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Users who have stopped the medication report a intense resurgence of hunger.
"It was like a trigger activating and I was suddenly ravenous," recalled one woman.
The struggle is compounded if patients have not developed permanent dietary or behavioural modifications during therapy.
Growing Adoption
Figures show that a significant number of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is more common among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts caution that while the jabs are effective tools for shedding pounds, they are not a permanent cure and long-term success relies on ongoing lifestyle management.
